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 Abstract 26 
Background 27 
Legionellosis is a life-threatening disease. The clinical superiority of quinolones or 28 
macrolides for treating patients with legionellosis has not been established. 29 
Methods 30 
We performed a systematic review and meta-analysis of studies reporting data for comparison 31 
of quinolones versus macrolides in the treatment of proven legionellosis published from 32 
01/01/1985 to 31/01/2013. We collected baseline aggregate patient characteristics. Studied 33 
outcomes included mortality, clinical cure, time to apyrexia, length of hospital-stay and 34 
occurrence of complication in each treatment group. Treatment effect was assessed using a 35 
Mantel-Haenszel random effects model.  36 
Results 37 
Among 1005 abstracts reviewed, 12 studies were selected (n=879 patients). No randomized 38 
controlled trial (RCT) was available. Mean age was 58.3 years, 27.7% were women and Fine 39 
score was ≥4 in 35.8%. Among 253 patients with quinolone monotherapy, 10 died (4.0%). 40 
Among 211 patients with macrolide monotherapy, 23 died (10.9%). The pooled odds ratio of 41 
death when treated by a quinolone versus macrolide was 0.5 (95%CI=[0.2 – 1.3], n=8 studies, 42 
464 patients). Length of stay was significantly lower in the quinolone monotherapy group. 43 
The difference was 3.0 days (95%CI=[0.7 – 5.3], p=0.001, n=3 studies, 263 patients). Both 44 
tests for heterogeneity were not significant (I2=0% for both, p=1). Other studied outcomes 45 
were not significantly different among treatment groups. 46 
Conclusion 47 
Few clinical data on legionellosis treatment are available. This first meta-analysis showed a 48 
trend toward a lower mortality rate and a significant decrease in length of hospital-stay in 49 
patients receiving quinolone. These results must be confirmed by a randomized clinical trial. 50 
51 
 Introduction 52 
Legionella pneumophila1 is the most common intracellular bacteria responsible for 53 
severe pneumonia.2 Its incidence was estimated to 1.2 per 100 000 inhabitants in 2010.3 Risk 54 
factors include a male gender, a smoking habit, a history of chronic lung disease or 55 
immunosuppression, as well as travel and stay in large buildings, including hotels and 56 
hospitals.1, 4-6 Prognosis factors include appropriateness and timing of initial antimicrobial 57 
therapy.7, 8 58 
Legionellosis mostly presents as a mild-to-moderate disease. Severe systemic cases 59 
have been reported.9-11 The overall mortality has been estimated to 12%,12 and to 15-20% in 60 
hospitalized patients. Mortality seems higher in nosocomial cases (15-40% versus 10-20% in 61 
community-acquired cases).13 As a result, when initiating an empiric antimicrobial therapy for 62 
a severe pneumonia, current guidelines recommend to perform urinary diagnostic tests and to 63 
initiate a treatment for both Streptococcus pneumoniae, the most frequent bacteria involved in 64 
severe pneumonia, and Legionella spp.14, 15 65 
Although erythromycin was the recommended treatment since the first reported outbreak of 66 
legionellosis, other agents have been developed. Recommended antimicrobials include 67 
quinolones and new macrolides. These recommendations are based on scarce data from in 68 
vitro and animal studies. Few data are available in humans and none allowed for a definitive 69 
conclusion. Consequently, the debate on which antimicrobial should be used in patients with 70 
legionellosis and/or to target Legionella spp. in patients with pneumonia is still ongoing.  71 
No randomized clinical trial (RCT) has been performed for efficacy comparison. We 72 
performed a systematic review and meta-analysis to compare the clinical efficacy of a 73 
monotherapy of quinolone or macrolide in the treatment of legionellosis. 74 
Material and methods 75 
Data sources 76 
 Using Cochrane methodology,16 we conducted a systematic search of the literature. PubMed, 77 
Embase and the Cochrane Central Register of Controlled Trials databases were searched from 78 
01/01/1985 to 01/31/2013. 79 
Search terms included: quinolone, fluoroquinolone, ofloxacin, ciprofloxacin, pefloxacin, 80 
trovafloxacin, levofloxacin, moxifloxacin, gatifloxacin, clinafloxacin, enoxacin, 81 
grepafloxacin, parfloxacin, norfloxacin, cinoxacin, macrolide, azithromycin, clarithromycin, 82 
erythromycin, spiramycin, roxithromycin. We also included related MeSH terms and Emtree 83 
entries. Two queries were performed. The first one (‘legionellosis query’, Table S1 as an 84 
example) aimed to identify studies providing data in legionellosis. In this query, ‘legionella’, 85 
‘legionnaire’ and ‘legionellosis’ terms were added to those aforementioned. In the second 86 
query, all RCTs performed to compare antimicrobial efficacy in community-acquired 87 
pneumonia were searched (‘RCTs in pneumonia query’, Table S2 as an example). In this 88 
second query, the term ‘pneumonia’ was added. 89 
We searched additional references among the following scientific conferences from 2000 to 90 
2012: Interscience Conference on Antimicrobial Agents and Chemotherapy, European 91 
Congress of Clinical Microbiology and Infectious Diseases, Infectious Disease Society of 92 
America and American Thoracic Society. Search terms included: ‘legionella’, ‘legionnaire’ 93 
and ‘legionellosis’. 94 
Study selection 95 
Title and abstract were independently assessed for eligibility by two authors (CB and RL). 96 
Full text of eligible studies and congress abstracts were independently examined for final 97 
inclusion. The opinion of a third investigator (YY) was asked in case of disagreement. 98 
Original studies providing data for comparison of the efficacy of quinolones and macrolides 99 
in legionellosis were included. In vitro and animal studies were excluded. Legionellosis 100 
 diagnosis had to be proven using urinary antigen, serology, sputum or tracheal aspirate 101 
analyzed by culture or PCR. 102 
Data extraction 103 
Data were extracted using a standardized form: patient population, number of participating 104 
centres, number of patients included, antimicrobial agents and doses used, clinical outcomes, 105 
severity assessed by the Fine score and adverse effects. 106 
Outcomes 107 
Primary outcome was mortality in each treatment group. Secondary outcomes included 108 
clinical cure, time to apyrexia, length of hospital stay, occurrence of complications defined by 109 
studies’ authors, need for mechanical ventilation and occurrence of adverse effects. 110 
Risk of bias assessment 111 
Risk of bias was assessed using the Newcastle-Ottawa scale.17 This 8-item scale is suggested 112 
by the Cochrane collaboration for risk of bias assessment of nonrandomized studies.16 113 
However we also used this scale for included RCTs. 114 
Statistical analysis 115 
The analysis focused on patients treated by antimicrobial monotherapy. β-lactams were not 116 
considered as effective anti-Legionella antimicrobials. We estimated pooled odds ratios and 117 
their 95% confidence intervals (95%CIs) comparing between quinolones and macrolides the 118 
probability of occurrence of qualitative outcomes. We estimated mean differences for time to 119 
apyrexia and length of hospital stay. Estimates were determined using a Mantel-Haenszel 120 
random effects model.16 Statistical heterogeneity was assessed using the chi-square test for 121 
heterogeneity and the I² statistic for measuring inconsistency. Analyses were performed using 122 
Review Manager v5.2 (Cochrane Collaboration, Oxford, United Kingdom). 123 
Results 124 
Identification of eligible studies 125 
 Databases queries identified 1005 articles and/or congress abstracts. Most were not 126 
eligible, and 96 full-text articles were retrieved and read for inclusion (Figure 1). Of those, 12 127 
were finally included. All were original articles.7, 18-28 Nine were observational cohort 128 
studies,7, 18, 20, 23-28 of which six were retrospective.18, 20, 23, 26-28 They were performed in Spain 129 
(n=4),7, 23-25 in France (n=2),18, 20 and Japan (n=2).26, 27 One was international.28 The three 130 
remaining studies were RCTs conducted in patients with pneumonia.19, 21, 22 Two of them 131 
were performed in the USA,21, 22 the third was international.19 Five of the 12 studies were 132 
conducted in a single centre.7, 20, 23, 24, 26 133 
Risk of bias 134 
Overall risk of bias is represented in Figure S1. Representativeness of general population was 135 
satisfactory. Patients included in observational studies were all patients with a proven 136 
diagnosis of legionellosis presenting in participating centres. Patients included in RCTs were 137 
representative of immunocompetent patients with community-acquired pneumonia. 138 
Ascertainment of therapy was performed using medical records or specific forms. All 139 
outcomes were prespecified and assessed using medical records or form completion. Follow 140 
up was adequate and long enough to ensure their assessment. 141 
With the exception that by Dournon et al.,18 no observational study controlled for 142 
confounding. Dournon et al. matched quinolone-treated patients with erythromycin-treated 143 
patient for age, duration of Legionnaires’ disease, immune status and requirement of 144 
mechanical ventilation. Patients treated with quinolone who received co-treatment with 145 
rifampicin and/or erythromycin were excluded from their analysis. Two RCTs did not stratify 146 
the randomization,19, 21  and the other one stratified randomization on centre.22  147 
Patient characteristics in included studies 148 
 Overall, 879 patients with legionellosis were included (10 to 292 patients per study). 149 
Mean age was 58.3 years, and 27.7% of patients were women (n=223/806). All patients were 150 
 hospitalized at baseline, 55.1% (n=411/746) had an underlying disease, 19.8% (n=89/449) 151 
had a chronic obstructive pulmonary disease, and 65.9% (n=270/410) had a smoking habit. 152 
Data on immunosuppression was available in only 2 studies.18, 27 In those, 63.6% (n=14/22) 153 
and 75% (n=45/60) of patients were immunocompromised. The Fine score was ≥ 4 in 35.8% 154 
(n=213/595).7, 23, 26-28 Overall, 71 of the 879 patients with legionellosis enrolled in included 155 
studies (8.1%) died during follow up. 156 
687 patients with legionellosis were treated with a quinolone (n=377, 54.9%) or 157 
macrolide (n=310, 45.1%) monotherapy (Table 1). In studies providing the information, 158 
26.0% (n=47/181) of quinolone-treated patients had a Fine score ≥ 4, versus 32.7% 159 
(n=36/110) of patients in the macrolide group.23, 26-28  160 
Outcomes 161 
Mortality was reported in 8 studies (Figure 2A).18, 20, 23-28  Overall mortality occurred 162 
in 10.9% of patients treated with a macrolide (n=23/211) versus 4.0% of patients treated with 163 
a quinolone (n=10/253). The combined odds ratio of death when treated with quinolones 164 
versus macrolides was 0.5 [95%CI, 0.2; 1.3]. 165 
Clinical cure was evaluated in 4 studies.19, 21-23 It was defined as resolution of signs 166 
and symptoms of pneumonia at the test-of-cure visit, performed depending on studies 167 
between day 1 and day 21 after the end of antimicrobial therapy. One study did not provide 168 
clinical cure definition.23 Clinical cure was observed in 100% of patients in 2 studies, 19, 21 169 
which could not be used for computations. In the 2 other studies, the pooled odds ratio of 170 
clinical cure for treatment with a quinolone versus a macrolide was 2.3 [95%CI, 0.3; 16.9] 171 
(Figure 2B).22, 23 172 
One study provided data for analysis of time to apyrexia.23 The time to apyrexia was 173 
shorter with quinolones than with macrolides, but the difference was not significant (mean 174 
difference, -4.8 hours [95%CI, -22.1; 12.5], Figure 2C). 175 
 Three studies were available for the comparison of length of hospital-stay (Figure 176 
2D).23, 27, 28 One of them showed a significant reduction of the length of hospital-stay with 177 
quinolones versus macrolides (-2.8, 95%CI, -5.4; -0.2).23 We found an overall significant 178 
mean reduction of 3.0 days with quinolones versus macrolides (95%CI, -5.3; -0.7). Test for 179 
heterogeneity was not significant (I²=0%, p=0.9). 180 
Two studies were included in the analysis of complications (Figure 2E).23, 25 These 181 
studies defined complicated legionellosis either as the apparition of pleural effusion, 182 
empyema, mechanical ventilation or septic shock;25 or renal failure, pleural effusion or 183 
admission to ICU.23 The combined odds ratio of complications when treated with quinolones 184 
versus macrolides, was 0.5 [95%CI, 0.1; 1.6]).  185 
Adverse effects 186 
In the only study providing data on adverse events,23 the three main reported events 187 
were gastrointestinal events (5 – 7%), liver abnormalities (2 – 3%) and phlebitis, which 188 
occurred more frequently in patients receiving clarithromycin than in those under 189 
levofloxacin therapy (p<0.01).  190 
Discussion 191 
This is the first systematic review and meta-analysis of the effectiveness of quinolones 192 
versus macrolides in the treatment of legionellosis. We found that despite a small number of 193 
studies addressing this issue in clinical settings – and a small number of patients in each study 194 
– quinolones seem to have a higher effectiveness than macrolides. Quinolone therapy was 195 
significantly associated with a shorter length of hospital-stay, and we observed a trend toward 196 
a reduced mortality, a higher clinical cure, a lower time to apyrexia, and a lower rate of 197 
complications in patients receiving a quinolone.  198 
Our analysis is unique. Published reviews on this topic did not use a systematic 199 
methodology for studies inclusion and results analysis.29, 30 In the absence of RCTs, the type 200 
 of analysis we conducted is the most accurate way to compare quinolones and macrolides 201 
effectiveness in patients with legionellosis and to improve management of this disease. 202 
 This question has been investigated in experimental models. In all but one of the 19 203 
intracellular models reviewed by Pedro-Botet and Yu, quinolones had a higher activity on 204 
Legionella pneumophila than macrolides.29 Levofloxacin was the most effective quinolone 205 
and azithromycin the most effective macrolide. In animal models of Legionella pneumophila 206 
infection, treatment with quinolones resulted in an increased survival.29 However, these 207 
experimental results may not be generalisable to humans.  208 
Despite a non-significant difference, results for all studied outcomes favoured 209 
quinolones. The absence of significance in these comparisons may be related to a lack of 210 
statistical power. However, none of the included studies attempted to control for confounding. 211 
Patients treated with macrolides had higher severity of disease. This might favour quinolones. 212 
Moreover, the macrolide agent used was mostly erythromycin, which is not the most effective 213 
macrolide agent as observed in in vitro studies.29 It was the only macrolide used in the study 214 
performed by Dournon et al,18 in which the number of deaths in the macrolide group 215 
accounted for 40% of overall deaths observed in our review, and with a mortality rate of 50% 216 
in this group. 217 
 This study has some other limitations. First, statistical methodology is limited by the 218 
observational design of most included studies. RCTs were not designed for a proper analysis 219 
in legionellosis. We used random effects modelling to limit inherent bias. Moreover, our 220 
results are strengthened by the absence of heterogeneity. Second, a small number of studies 221 
were included. Legionellosis is a rare disease. The systematic strategy used for inclusion 222 
aimed to minimize misidentifications and to limit publication bias. However, reporting bias is 223 
a recurrent problem in systematic reviews and unpublished work could not be retrieved by our 224 
search strategy. Third, we were not able to perform subgroup analysis and/or to adjust on 225 
 disease severity or prognosis factors. Finally, we could not perform a face-to-face comparison 226 
of individual quinolones and macrolides as individual data were not available.  227 
In light of our results, should we prefer quinolones or macrolides when treating a 228 
patient with a proven Legionella pneumonia? Our analysis does not provide a high level of 229 
evidence for conclusion. When answering this thorny question, risks associated with the 230 
administration of these antimicrobials should be considered. Quinolones are generally well-231 
tolerated drugs; serious adverse events are rare. There is a rare risk of cardiac toxicity with 232 
macrolides, but azithromycin is generally considered to be free of serious adverse effects.31-33 233 
Both quinolones and macrolides have been associated with an increased risk of developing a 234 
Clostridium difficile infection, with a higher risk for quinolones.34 The emergence of bacterial 235 
resistance in the digestive microbiota has been documented with quinolones,35 but such 236 
consideration should not restrain their use when treating a potentially fatal infection. 237 
We believe that quinolones might be preferred for proven legionellosis, especially in 238 
patients with severe legionellosis. Empirical antimicrobial therapy for patients with severe 239 
pneumonia might benefit of a combination of a β-lactam and a quinolone, when a Legionella 240 
infection is suspected. However, in patients with mild pneumonia from uncertain origin, the 241 
potential negative impact of quinolones on the digestive microbiota should be balanced with 242 
their possible higher efficacy than macrolides. 243 
This analysis should be confirmed by an international trial. With almost 5000 cases reported 244 
in Europe by the European Legionnaires’ Disease Surveillance Network in 2011,36 such trial 245 
would bring a definitive conclusion to the recurrent question of antimicrobial selection in 246 
Legionella pneumonia. 247 
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354 
 Figures 355 
Figure 1. Flowchart of studies inclusion. RCTs, randomized controlled trials.  356 
808 records identified through
the 'legionellosis' query
96 full-text articles 
assessed for eligibility
12 studies included 
in analysis
84 full-text articles excluded:
- no comparison in legionellosis, n=49
- no data for comparison of quinolones and macrolides, n=32
- not a original study, n=2
- congress abstract published as article, n=1
909 records excluded:
- review, n=480
- not a comparative study, n=202
- not a clinical study, n=175
- not a study in legionellosis or pneumonia, n=52
242 records identified through 
the 'RCTs in pneumonia' query
1005 records screened after
duplicates removed
 357 
358 
  Figure 2. Comparison of quinolones and macrolides effectiveness in Legionella pneumonia. 359 
A, analysis of mortality; B, analysis of clinical cure; C, analysis of the time to apyrexia 360 
(hours); D, analysis of length of hospital stay (days); E, analysis of the occurrence of 361 
complications. 362 
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M-H, Random, 95% CI
0.40 [0.06, 2.57]
0.33 [0.01, 12.82]
1.38 [0.06, 34.30]
0.10 [0.00, 3.24]
0.69 [0.16, 2.87]
0.35 [0.02, 8.02]
1.17 [0.04, 34.52]
0.66 [0.05, 7.89]
0.54 [0.23, 1.26]
Quinolones Macrolides Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Quinolones Favours Macrolides
Study or Subgroup
Fogarty 2004
Blazquez-Garrido 2005
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.83, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 0.85 (P = 0.39)
Events
4
142
146
Total
5
143
148
Events
5
65
70
Total
11
65
76
Weight
62.5%
37.5%
100.0%
M-H, Random, 95% CI
4.80 [0.40, 58.01]
0.73 [0.03, 18.04]
2.36 [0.33, 16.92]
Quinolones Macrolides Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Macrolides Favours Quinolones
Study or Subgroup
Blazquez-Garrido 2005
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Mean
105.6
SD
58.6
Total
143
143
Mean
110.4
SD
59.2
Total
65
65
Weight
100.0%
100.0%
IV, Random, 95% CI
-4.80 [-22.10, 12.50]
-4.80 [-22.10, 12.50]
Quinolones Macrolides Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours Quinolones Favours Macrolides
Study or Subgroup
Blazquez-Garrido 2005
Nakamura 2009
Griffin 2010
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 2 (P = 0.94); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)
Mean
4.4
29.6
8.9
SD
1.83
16.3
7.3
Total
143
12
16
171
Mean
7.2
32.3
12.7
SD
10.69
21.7
8.3
Total
65
4
23
92
Weight
77.3%
1.0%
21.8%
100.0%
IV, Random, 95% CI
-2.80 [-5.42, -0.18]
-2.70 [-25.88, 20.48]
-3.80 [-8.73, 1.13]
-3.02 [-5.32, -0.72]
Quinolones Macrolides Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours Quinolones Favours Macrolides
Study or Subgroup
Blazquez-Garrido 2005
Sabria 2005
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.33; Chi² = 1.42, df = 1 (P = 0.23); I² = 29%
Test for overall effect: Z = 1.25 (P = 0.21)
Events
1
9
10
Total
143
54
197
Events
3
18
21
Total
65
76
141
Weight
24.0%
76.0%
100.0%
M-H, Random, 95% CI
0.15 [0.01, 1.43]
0.64 [0.26, 1.57]
0.45 [0.13, 1.57]
Quinolones Macrolides Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Quinolones Favours Macrolides
A
B
C
D
E
 364 
 Table 365 
Table 1. Main characteristics and outcomes of the studies included in the analysis according to monotherapy treatment group. AZM, 366 
azithromycin; CIP, ciprofloxacin; CLR, clarithromycin; ERY, erythromycin; LVX, levofloxacin; RXM, roxithromycin; M, macrolide 367 
monotherapy; OFX, ofloxacin; PEF, pefloxacin; PAZ, pazufloxacin; Q, quinolone monotherapy; SD, standard deviation; SPX, sparfloxacin; 368 
TVA, trovafloxacin. Missing data of presented variables were not available in the corresponding studies. 369 
 370 
Study   Enrolment  period 
Number of 
patients 
with 
legionellosis 
  Agent(s) used (n) 
  
Mean age 
(years)   
Proportion 
of women 
(%) 
  
Underlying 
disease, n (%)   
Fine score ≥4, 
n (%)   
Overall 
mortality, n 
(%) 
  
Mean time to 
apyrexia, hours 
(SD) 
  
Mean hospital 
stay, days 
(SD) 
  
Secondary  
complication, 
n (%) 
 
Clinical cure, 
n (%) 
 
Q M  Q M 
 
Q M 
 
Q M 
 
Q M 
 
Q M 
 
Q M 
 
Q M 
 
Q M 
 
Q M  Q M 
Dournon 199018  1980-1988 7 20  PEF ERY   49.8   30        2 (28.6) 
10 
(50.0)          
 
  
Lode 199519  1990-1992 1 7  SPX ERY                          1 (100) 
1 
(100) 
Gacouin 200220  1990-2001 3 2                 2 (66.7) 
2 
(100)          
 
  
Sokol 200221  1998-1999 7 7  TVA CLR                          7 (100) 
7 
(100) 
Fogarty 200422  1997-2000 5 11  LVX ERY                          4 (80) 5 (45.5) 
Blazquez-Garrido 
200523  2001 143 65  LVX 
AZM, 
CLR           
29 
(20.3) 
11 
(16.9)  
1 
(0.7) 0 (0)  
105.6 
(58.6) 
110.4 
(59.2)  
4.4 
(1.8) 
7.2 
(10.7)  
1 
(0.7) 
3 
(4.6) 
 142 
(99.3) 
65 
(100) 
Querol-Ribelles 200524  2000-2003 8 3  LVX CLR              0 (0) 1 (33.3)          
 
  
Sabria 200525  1995-2004 54 76  
LVX 
(50), 
OFX (4) 
ERY, CLR 
 
57.4 60 
 
33.3 18.5 
 
37 
(66.5) 
59 
(77.6)     
3 
(5.6) 
6 
(7.9)  48.0 77.1  7.6 9.9  
9 
(10.7) 
18 
(23.7) 
 
  
Haranaga 200626  1996-2005 9 18  CIP ERY  69.7 62.8  33 22  8 (88.9) 
12 
(66.7)  
6 
(66.7) 
9 
(50.0)  0 (0) 
2 
(11.1)  84.0 96.0  16.7 20.0    
 
  
Nakamura 200927  1999-2008 12 4  
CIP 
(10), 
PAZ (2) 
 
 
  
 
  
 
  
 
5 
(41.2) 
2 
(50.0)  
1 
(8.3) 0 (0)     
29.6 
(16.3) 
32.3 
(21.7)    
 
  
Griffin 201028  2001-2008 17 23  LVX AZM (13), CLR (10)     18.7 26.1     
7 
(41.2) 
14 
(60.9)  
1 
(5.9) 
1 
(4.3)     
8.9 
(7.3) 
12.7 
(8.3)    
 
    
Viasus 20137   1995-2010 111 74   LVX 
ERY, 
RXM, 
CLR, 
AZM 
  
    
  
   
  
    
  
    
  
    
  
    
  
7.0 10.0 
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